The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma
Neuro-Oncology · 2024
DOI: 10.1093/neuonc/noae114 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Mohammad H Abu-Arja und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Pediatrics, Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Hou…. Hauptthemen laut MEDLINE: Medulloblastoma, Cisplatin, Proton Therapy, Cerebellar Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Hearing loss (HL) is associated with worse neurocognitive outcomes among patients with medulloblastoma. We aimed to identify risk factors associated with severe HL and to evaluate the generalizability of a published HL calculator among patients treated with passive scattering proton therapy (PSPT) and cisplatin.
Methods
We identified patients aged 3–21 years who were treated at our centers between 2007 and 2022. Audiograms were graded using the International Society of Pediatric Oncology (SIOP) Boston scale. Time to grades 3–4 HL was evaluated using Kaplan–Meier and multivariable Cox models to estimate hazard ratios and 95% confidence intervals (CI).
Results
Seventy-nine patients were treated with PSPT at a median age of 7.5 years (range: 3.1–21.1). The mean cochlear dose (Dmc) (±SD) was 31.5 ± 8.5 Gy, and the cumulative cisplatin dose was 295 ± 50 mg/m2. Fifty-nine patients (75%) received amifostine. Patients completed a median of 9 audiograms (range: 4–22) with a median audiogram follow-up of 49 months (range: 6–177). Twenty-seven patients (34%) had grades 3–4 HL. In adjusted Cox models, only higher Dmc (HR = 1.12, 95% CI:1.06–1.18) was associated with grades 3–4 HL. The predicted 3-year incidence of grades 3–4 HL was 40.0% (95% CI: 21.3–66.3) and 66.7% (95% CI: 35.4–93.7) for children with Dmc ≥36 Gy and age at radiotherapy ≥7 and <7 years, respectively (P = .042). It was 8.9% (95% CI: 2.3–31.6) and 15.6% (95% CI: 5.3–41.1) for children with Dmc <36 Gy and age at radiotherapy ≥7 and <7 years, respectively (P = .78).
Conclusions
Children <7 years at radiotherapy with a Dmc ≥36 Gy are at higher risk for HL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology/Oncology, Department of Pediatrics, Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.
- Center for Cancer and Blood Disorders, Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, Denver, Colorado, USA.
- Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Mohammad H Abu-Arja, Holly B Lindsay
Zitieren
APA
Abu-Arja, M. H., Brown, A. L., Su, J. M., Okcu, M. F., Lindsay, H. B., McGovern, S. L., McAleer, M. F., Grosshans, D. R., Chintagumpala, M. M., & Paulino, A. C. (2024). The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae114
Vancouver
Abu-Arja MH, Brown AL, Su JM, Okcu MF, Lindsay HB, McGovern SL, et al. The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma. Neuro-Oncology. 2024. doi:10.1093/neuonc/noae114
BibTeX
@article{AbuArja2024,
author = {Abu-Arja, Mohammad H and Brown, Austin L and Su, Jack M and Okcu, M Fatih and Lindsay, Holly B and McGovern, Susan L and McAleer, Mary Frances and Grosshans, David R and Chintagumpala, Murali M and Paulino, Arnold C},
title = {The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma},
journal = {Neuro-Oncology},
year = {2024},
doi = {10.1093/neuonc/noae114}
}
EUVIMED